November 13, 2017 / 11:40 AM / a month ago

BRIEF-Jounce Therapeutics reports Q3 loss $0.13/shr

Nov 13 (Reuters) - Jounce Therapeutics Inc

* Jounce Therapeutics reports third quarter 2017 financial results

* Q3 loss per share $0.13

* Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S

* Jounce Therapeutics Inc- ‍remain on track to announce preliminary efficacy data for phase 1/2 iconic study in 1H 2018​

* Jounce Therapeutics Inc - ‍jounce has narrowed its financial guidance previously provided for full year 2017​

* Jounce Therapeutics Inc- ‍now expects to use approximately $100.0 million to $110.0 million in cash for full year 2017​

* Jounce Therapeutics Inc- ‍collaboration revenue was $18.1 million for Q3 of 2017, compared to $16.9 million for same period in 2016​

* Jounce Therapeutics Inc- ‍as of Sept 30, 2017, cash, cash equivalents and investments were $283.4 million, compared to $257.4 million as of Dec 31, 2016​

* Jounce Therapeutics - now expects collaboration revenue from non-cash amortization of Celgene upfront payment​ for FY 2017 to be $70 million to $75 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below